###begin article-title 0
The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel
###end article-title 0
###begin p 1
This document may be redistributed and reused, subject to .
###end p 1
###begin title 2
Summary
###end title 2
###begin p 3
The extracellular matrix (ECM) can induce chemotherapy resistance via AKT-mediated inhibition of apoptosis. Here, we show that loss of the ECM protein TGFBI (transforming growth factor beta induced) is sufficient to induce specific resistance to paclitaxel and mitotic spindle abnormalities in ovarian cancer cells. Paclitaxel-resistant cells treated with recombinant TGFBI protein show integrin-dependent restoration of paclitaxel sensitivity via FAK- and Rho-dependent stabilization of microtubules. Immunohistochemical staining for TGFBI in paclitaxel-treated ovarian cancers from a prospective clinical trial showed that morphological changes of paclitaxel-induced cytotoxicity were restricted to areas of strong expression of TGFBI. These data show that ECM can mediate taxane sensitivity by modulating microtubule stability.
###end p 3
###begin title 4
SIGNIFICANCE
###end title 4
###begin p 5
###xml 584 589 584 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THBS1</italic>
###xml 0 911 0 911 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Extracellular matrix (ECM) proteins such as fibronectin induce resistance to chemotherapy via activation of intracellular survival pathways. We now show that the ECM protein TGFBI mediates specific sensitization to paclitaxel by inducing stabilization of microtubules via integrin-mediated signaling pathways. Analysis of paclitaxel-treated ovarian cancers from a prospective clinical trial shows TGFBI protein expression in areas of paclitaxel-induced cytotoxicity. Bioinformatic analysis of three microarray expression data sets from 223 ovarian and breast cancer samples show that <italic>TGFBI</italic> expression is tightly coregulated with other genes that induce paclitaxel sensitization such as <italic>THBS1</italic>. These data show that paclitaxel response can be modulated by ECM proteins and raise the prospect of improving the therapeutic index of taxanes via manipulation of these proteins and their downstream signaling pathways.</bold>
Extracellular matrix (ECM) proteins such as fibronectin induce resistance to chemotherapy via activation of intracellular survival pathways. We now show that the ECM protein TGFBI mediates specific sensitization to paclitaxel by inducing stabilization of microtubules via integrin-mediated signaling pathways. Analysis of paclitaxel-treated ovarian cancers from a prospective clinical trial shows TGFBI protein expression in areas of paclitaxel-induced cytotoxicity. Bioinformatic analysis of three microarray expression data sets from 223 ovarian and breast cancer samples show that TGFBI expression is tightly coregulated with other genes that induce paclitaxel sensitization such as THBS1. These data show that paclitaxel response can be modulated by ECM proteins and raise the prospect of improving the therapeutic index of taxanes via manipulation of these proteins and their downstream signaling pathways.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 145 187 145 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib30 bib38" ref-type="bibr">McGuire et&#160;al., 1996; Sandler et&#160;al., 2006</xref>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
Taxanes are microtubule-stabilizing drugs that have been extensively used as effective chemotherapeutic agents in the treatment of solid tumors (McGuire et al., 1996; Sandler et al., 2006). However, taxane resistance limits clinical utility to approximately 50% of patients with breast or ovarian cancer. Identification of mechanisms of taxane resistance that are therapeutically accessible is, therefore, required to improve treatment.
###end p 7
###begin p 8
###xml 105 167 105 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib40 bib20 bib39" ref-type="bibr">Schiff et&#160;al., 1979; Ibrado et&#160;al., 1998; Scatena et&#160;al., 1998</xref>
###xml 281 298 281 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib37" ref-type="bibr">Peer et&#160;al., 2004</xref>
###xml 326 342 326 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib50" ref-type="bibr">Tan et&#160;al., 2002</xref>
###xml 376 394 376 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2" ref-type="bibr">Anand et&#160;al., 2003</xref>
###xml 438 456 438 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib19" ref-type="bibr">Huang et&#160;al., 1997</xref>
###xml 573 653 573 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib55 bib11 bib1 bib54" ref-type="bibr">Zhang et&#160;al., 1998; Gon&#231;alves et&#160;al., 2001; Alli et&#160;al., 2002; Wang et&#160;al., 2004</xref>
###xml 748 772 745 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10" ref-type="bibr">Giannakakou et&#160;al., 1997</xref>
###xml 985 1047 982 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib11 bib4 bib15" ref-type="bibr">Gon&#231;alves et&#160;al., 2001; Barlow et&#160;al., 2002; Hari et&#160;al., 2006</xref>
###xml 1086 1107 1080 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib31" ref-type="bibr">Mozzetti et&#160;al., 2005</xref>
###xml 1177 1194 1171 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1" ref-type="bibr">Alli et&#160;al., 2002</xref>
Paclitaxel, a prototype taxane, stabilizes microtubule polymers leading to mitotic arrest and apoptosis (Schiff et al., 1979; Ibrado et al., 1998; Scatena et al., 1998). General mechanisms of drug resistance, including overexpression of the ABC/MDR transporter family of proteins (Peer et al., 2004), delayed G2/M transition (Tan et al., 2002), defective mitotic checkpoints (Anand et al., 2003), and alterations in apoptosis regulation (Huang et al., 1997), may alter paclitaxel sensitivity. More specifically, alterations of microtubules induce severe taxane resistance (Zhang et al., 1998; Goncalves et al., 2001; Alli et al., 2002; Wang et al., 2004). These include beta-tubulin mutations which may decrease paclitaxel binding to microtubules (Giannakakou et al., 1997). Alternatively, factors that increase the ratio of unstable to stable microtubules induce profound taxane resistance. This may occur by mutations in nonpaclitaxel binding sites, alterations in tubulin isoforms (Goncalves et al., 2001; Barlow et al., 2002; Hari et al., 2006), overexpression of beta-III tubulin (Mozzetti et al., 2005), and overexpression of the microtubule-associated protein stathmin (Alli et al., 2002).
###end p 8
###begin p 9
###xml 89 111 89 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12" ref-type="bibr">Gundersen et&#160;al., 1984</xref>
###xml 422 485 419 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib6 bib35 bib13" ref-type="bibr">Cook et&#160;al., 1998; Palazzo et&#160;al., 2004; Gundersen et&#160;al., 1994</xref>
Cells contain subsets of stable and dynamic microtubules that are functionally distinct (Gundersen et al., 1984), and there is strong evidence that extracellular stimuli regulate microtubule stability. Serum starvation or loss of direct cell contact results in loss of microtubule stabilization, while fibronectin-mediated adhesion or treatment of cells with lysophosphatidic acid or TGFbeta induce microtubule stability (Cook et al., 1998; Palazzo et al., 2004; Gundersen et al., 1994). Whether extracellular matrix (ECM) modulation of microtubule stability may alter paclitaxel sensitivity has been, to date, unknown.
###end p 9
###begin p 10
###xml 197 205 <span type="species:ncbi:9606">patients</span>
We describe here the identification of TGFBI (transforming growth factor beta induced) as an ECM protein that induces microtubule stabilization and modulates paclitaxel sensitivity in vitro and in patients receiving paclitaxel therapy.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
TGFBI Is Significantly Underexpressed in an Ovarian Cancer Cell Line Model of Paclitaxel Resistance
###end title 12
###begin p 13
###xml 226 243 226 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr">Duan et&#160;al., 1999</xref>
###xml 340 348 340 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figure&#160;1</xref>
###xml 598 600 598 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CP</italic>
###xml 602 606 602 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 608 625 608 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib52" ref-type="bibr">Ueta et&#160;al., 2001</xref>
###xml 628 633 628 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HMGA1</italic>
###xml 635 678 635 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18 bib24" ref-type="bibr">Huang et&#160;al., 1994; Kasparkova et&#160;al., 2003</xref>
###xml 685 690 685 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL1</italic>
###xml 692 711 692 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib51" ref-type="bibr">Taxman et&#160;al., 2003</xref>
###xml 714 722 714 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figure&#160;1</xref>
###xml 725 733 725 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Table S1</xref>
###xml 741 758 741 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Supplemental Data</xref>
To identify genes associated with the acquisition of paclitaxel resistance, we studied the ovarian cancer cell line SKOV-3TR, which was derived from SKOV-3 by prolonged and repeated exposure to increasing doses of paclitaxel (Duan et al., 1999). We compared the expression profiles of the parent and resistant lines using cDNA microarrays (Figure 1A) after confirming that SKOV-3 and SKOV-3TR were isogenic by short tandem repeats genotyping (data not shown). Examination of the most differentially expressed genes showed several candidates previously identified in chemotherapy response including CP, SOD2 (Ueta et al., 2001), HMGA1 (Huang et al., 1994; Kasparkova et al., 2003), and CXCL1 (Taxman et al., 2003) (Figure 1A; Table S1 in the Supplemental Data available with this article online).
###end p 13
###begin p 14
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 259 279 253 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib46" ref-type="bibr">Skonier et&#160;al., 1992</xref>
###xml 362 404 356 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib22 bib5" ref-type="bibr">Jeong and Kim, 2004; Billings et&#160;al., 2002</xref>
###xml 485 490 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 492 500 486 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figure&#160;1</xref>
###xml 807 816 801 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figures 1</xref>
The most underexpressed gene in the taxane-resistant line was transforming growth factor beta induced (TGFBI; also known as Big-h3, beta-ig H3, and keratoepithelin), which is an extracellular matrix protein whose secretion is induced by TGFbeta1 stimulation (Skonier et al., 1992). Its functions include cell adhesion to the ECM and integrin-mediated signaling (Jeong and Kim, 2004; Billings et al., 2002). Quantitative real-time PCR confirmed striking underexpression (>1000 fold) of TGFBI (Figure 1B). This underexpression was maintained after growing the cells without paclitaxel for several months (data not shown). Immunocytochemistry using anti-TGFBI antibody on paraffin-embedded cell blocks and immunoblotting of conditioned media from the two cell lines showed very low secretion of TGFBI protein (Figures 1C and 1D) from the resistant SKOV-3TR cells.
###end p 14
###begin title 15
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
Loss of TGFBI Is Sufficient to Induce Paclitaxel Resistance
###end title 15
###begin p 16
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 511 520 511 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figures 1</xref>
To examine the effect of loss of TGFBI expression on paclitaxel sensitivity, stable transfected cell lines expressing short interfering RNAs (siRNA) against TGFBI were generated from the parental SKOV-3 line. Two vectors targeting 21 bp sequences at nucleotides 810 or 1318 of the TGFBI coding sequence were transfected independently or together to generate stable cell line pools SKOV3-A, SKOV3-K, and SKOV3-AK, respectively. Effective knockdown (KD) of TGFBI mRNA and protein was achieved in all three lines (Figures 1B and 1D and data not shown).
###end p 16
###begin p 17
###xml 194 211 194 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib53" ref-type="bibr">Wang et&#160;al., 1998</xref>
###xml 237 242 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 409 417 409 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figure&#160;1</xref>
###xml 523 528 523 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 566 574 566 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figure&#160;1</xref>
###xml 604 613 604 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S1</xref>
The effect of paclitaxel treatment on these cells was examined. Early apoptosis was measured after 48 hr of paclitaxel exposure by flow cytometry of cells stained with FITC-annexin V and 7-AAD (Wang et al., 1998). Cell lines that lacked TGFBI (SKOV-3TR and TGFBI-KD cells) showed a significantly lower percentage of paclitaxel-induced apoptosis (p < 0.001, one-way ANOVA) in contrast to control SKOV-3 cells (Figure 1E). Caspase 3/7 activation 48 hr following paclitaxel treatment was significantly reduced in SKOV-3TR and TGFBI-KD cells (p < 0.001, two-way ANOVA) (Figure 1F) as was caspase 3 cleavage (Figure S1A).
###end p 17
###begin p 18
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 201 211 201 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figures S1</xref>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 347 355 347 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figure&#160;1</xref>
###xml 366 374 366 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figure&#160;1</xref>
###xml 384 393 384 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S1</xref>
###xml 407 416 407 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S1</xref>
Analysis of 9 ovarian and 11 breast cancer cell lines showed that TGFBI expression was significantly lower in resistant (n = 7) cells (p = 0.027, two-way ANOVA), and this was independent of cell type (Figures S1B and S1C). Importantly, transient knockdown of TGFBI using a pool of four siRNAs in four additional ovarian cancer cell lines, OVCAR3 (Figure 1G), TR175 (Figure 1H), 1847 (Figure S1D), and PE01 (Figure S1E), resulted in significant resistance to paclitaxel-induced caspase activation (p < 0.001, two-way ANOVA). These results were confirmed using at least two individual siRNAs in each cell line (data not shown).
###end p 18
###begin p 19
###xml 101 123 101 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26" ref-type="bibr">Lamendola et&#160;al., 2003</xref>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCB6</italic>
###xml 210 227 210 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib8" ref-type="bibr">Duan et&#160;al., 2005</xref>
###xml 419 428 419 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 522 527 522 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 552 557 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
SKOV-3TR cells have accumulated multiple paclitaxel resistance mechanisms during in vitro selection (Lamendola et al., 2003). For example, expression profiling of SKOV-3TR shows upregulation of MDR1 and ABCB6 (Duan et al., 2005; data not shown). The intensity values of a fluorescent derivative of paclitaxel were lower in SKOV-3TR compared to parental SKOV-3 and could be corrected using the MDR1 inhibitor verapamil (Figure S2A). However, induction of paclitaxel resistance in SKOV-3 cells by specific downregulation of TGFBI strongly suggested that TGFBI was an important component of the resistance shown in SKOV-3TR.
###end p 19
###begin p 20
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 206 215 206 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 366 375 366 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 452 457 452 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
To investigate how TGFBI modulated response to paclitaxel, we analyzed common resistance mechanisms using TGFBI-KD cells. Intracellular intensity of fluorescent paclitaxel was not different after TGFBI-KD (Figure S2A). In addition, apoptosis induction using UV, cisplatin, or nocodazole treatment was not significantly different between TGFBI-KD and parental cells (Figure S2B). These data show that paclitaxel resistance arising from specific loss of TGFBI is not caused by nonspecific alterations in apoptotic or multi-drug-resistance pathways.
###end p 20
###begin p 21
###xml 89 107 89 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2" ref-type="bibr">Anand et&#160;al., 2003</xref>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 183 192 183 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 359 368 359 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 490 508 490 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2" ref-type="bibr">Anand et&#160;al., 2003</xref>
###xml 511 520 511 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 860 873 860 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib34" ref-type="bibr">Nicklas, 1997</xref>
###xml 1075 1097 1075 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib28" ref-type="bibr">Logarinho et&#160;al., 2004</xref>
###xml 1361 1370 1361 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 1452 1468 1452 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib50" ref-type="bibr">Tan et&#160;al., 2002</xref>
###xml 1537 1542 1537 1542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 1881 1899 1881 1899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2" ref-type="bibr">Anand et&#160;al., 2003</xref>
###xml 1902 1911 1902 1911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 1947 1952 1947 1952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
Abnormal mitotic checkpoints have previously been shown to confer paclitaxel resistance (Anand et al., 2003). Mitotic SKOV-3 cells lacking TGFBI showed a slight increase in prophase (Figure S2C), but no significant difference in the duration of mitotic progression was observed when measured by time-lapse imaging of individual cells (p = 0.1, one-way ANOVA, Figure S2D). A characteristic feature of overriding mitotic checkpoints is persistence of checkpoint proteins following metaphase (Anand et al., 2003). Figure S2E shows no significant difference (p = 0.4, Chi Square test) between KD and control cell lines in the proportion of postmetaphase cells showing persistent cyclin B1 staining. BubR1, a mitotic checkpoint protein expressed prior to anaphase, is thought to sense tension across the spindle when chromosomes are aligned in the metaphase plate (Nicklas, 1997). Correct sensing of spindle tension leads to degradation of BubR1 and anaphase transition. Spindle poisons such as nocodazole and paclitaxel abolish tension leading to persistent expression of BubR1 (Logarinho et al., 2004). Cells with abnormal BubR1 function progress to anaphase in spite of exposure to spindle poisons. The expression of BubR1 in wild-type, KD, and SKOV-3TR cells was normal following nocodazole treatment indicating that sensing of spindle tension was not impaired (Figure S2F). Delayed cell-cycle transition has been shown to confer paclitaxel resistance (Tan et al., 2002). There was no difference in cell-cycle profiles of nonsynchronized TGFBI-KD or SKOV-3TR cells as compared to mock-transfected SKOV-3 (data not shown). To test cell-cycle profiles in synchronized cells, we used HeLa cells as they express comparable levels of TGFBI to those of SKOV-3 (data not shown) and are a well characterized cell-cycle model with intact mitotic checkpoints and are sensitive to paclitaxel (Anand et al., 2003). Figure S2G shows that transient knockdown of TGFBI had no effect on cell-cycle progression in HeLa cells synchronized in G1 by double thymidine block.
###end p 21
###begin title 22
TGFBI Restores Paclitaxel-Induced Tubulin Polymerization
###end title 22
###begin p 23
###xml 96 120 96 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib41" ref-type="bibr">Schiff and Horwitz, 1980</xref>
###xml 154 178 154 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10" ref-type="bibr">Giannakakou et&#160;al., 1997</xref>
###xml 313 322 312 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figures 2</xref>
###xml 335 344 334 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S3</xref>
###xml 583 592 582 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S3</xref>
###xml 695 704 694 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figures 2</xref>
###xml 717 726 716 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S3</xref>
###xml 788 793 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 820 825 819 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 967 976 966 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figures 2</xref>
###xml 989 998 988 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S3</xref>
Microtubule bundle formation has been described as the hallmark of paclitaxel exposure in vivo (Schiff and Horwitz, 1980) and is lost in resistant cells (Giannakakou et al., 1997). Indeed, SKOV-3 cells treated with 2 muM paclitaxel for 24 hr showed striking paclitaxel-induced bundles (PIBs) in interphase cells (Figures 2A and 2B and Figure S3A) and severe failure of mitotic spindle organization. Mitotic cells showed a prometaphase-like state where chromosomes formed ring-like structures around centrally radiating microtubule fibers, which we termed mitosis-like wheels (MLWs) (Figure S3B). In contrast, a minority of SKOV-3TR cells showed PIBs (2.4% versus 93%) or MLWs (1.7% versus 92%) (Figures 2C and 2D and Figure S3A). Importantly, SKOV-3TR cells transfected with a myc-tagged TGFBI expression plasmid (pCSMT-TGFBI) showed a modest increase (12% versus 3.7%) in the proportion of PIBs and MLWs following paclitaxel treatment (p < 0.001, two-sided t test) (Figures 2E and 2F and Figure S3A).
###end p 23
###begin p 24
###xml 348 370 348 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12" ref-type="bibr">Gundersen et&#160;al., 1984</xref>
###xml 387 392 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 554 562 554 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figure&#160;2</xref>
###xml 587 592 587 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 696 704 696 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figure&#160;2</xref>
###xml 750 755 750 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 967 1029 967 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib11 bib4 bib15" ref-type="bibr">Gon&#231;alves et&#160;al., 2001; Barlow et&#160;al., 2002; Hari et&#160;al., 2006</xref>
###xml 1149 1158 1149 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figures 2</xref>
Paclitaxel induces microtubule stabilization, and posttranslational modifications of tubulin, such as detyrosination or acetylation, accumulate in these stable microtubules. Detyrosination exposes Glu residues at the carboxy terminus of alpha-tubulin that can be detected using antibodies and, therefore, used as a marker of microtubule stability (Gundersen et al., 1984). Cells lacking TGFBI (SKOV-3TR, SKOV3-K) showed impaired paclitaxel-induced microtubule stabilization as evidenced by decreased Glu-tubulin formation following paclitaxel treatment (Figure 2G). Similarly, transient TGFBI-KD of SKOV-3 using pooled siRNAs resulted in intermediate reduction of paclitaxel induced Glu-tubulin (Figure 2G). These data suggest that selective loss of TGFBI induces paclitaxel resistance at the level of microtubules. Alteration of microtubule function leading to paclitaxel resistance is associated with increased ratios of soluble to insoluble intracellular tubulin (Goncalves et al., 2001; Barlow et al., 2002; Hari et al., 2006). Consistent with this, SKOV-3TR and SKOV3-K cells showed increased soluble tubulin compared to parental SKOV-3 cells (Figures 2H and 2I).
###end p 24
###begin title 25
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
TGFBI Silencing Results in Increased Mitotic Abnormalities in Cancer Cell Lines
###end title 25
###begin p 26
###xml 200 253 200 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib11 bib25" ref-type="bibr">Gon&#231;alves et&#160;al., 2001; Kline-Smith and Walczak, 2004</xref>
###xml 434 442 434 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 470 475 470 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 551 556 551 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 745 753 745 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 792 800 792 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 1006 1014 1006 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 1136 1144 1136 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 1206 1211 1206 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 1362 1370 1362 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
Tight regulation of tubulin dynamics is crucial for normal completion of mitosis, and alterations in microtubules that induce taxane resistance can cause geometric deformities in the mitotic spindle (Goncalves et al., 2001; Kline-Smith and Walczak, 2004). Mitotic cells from SKOV-3TR had a significantly higher proportion of abnormal mitosis compared to control SKOV-3 cells (14% versus 1.9%, respectively; p < 0.001, two-way ANOVA) (Figure 3C). To confirm that loss of TGFBI was sufficient to induce mitotic abnormalities, we examined the effects of TGFBI knockdown on mitosis in SKOV3-K and SKOV3-A cells. Strikingly, abnormal mitotic figures were observed including monopolar spindle formation, multiple centrosomes with multipolar spindles (Figure 3A), and abnormal spindle architecture (Figure 3B) in stably transfected cells 9-30 days following transfection. Control cells transfected with empty vector and examined in parallel at the same time points did not show significant mitotic abnormalities (Figure 3C). In addition, interphase cells showed a significant increase in the proportion of cells with centrosome amplification (Figure 3D). These phenotypes were also observed 48 hr after transient TGFBI-KD of HeLa, 1847, and OVCAR3 cell lines and also in SKOV-3 using A810 and K1318 constructs, although lower proportions of abnormal mitoses were seen (Figure 3E and data not shown).
###end p 26
###begin p 27
###xml 410 419 410 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S4</xref>
To examine whether direct colocalization of TGFBI with microtubules or centrosomes could explain these findings, we characterized the subcellular localization of carboxy-terminal tagged TGFBI (with green fluorescent protein or myc epitopes). Tagged-TGFBI localized in the Golgi apparatus and in intracellular vesicles along microtubule fibers and accumulated at cellular protrusions consistent with secretion (Figure S4). No tagged-TGFBI was seen in the nucleus of interphase cells and there was no localization in mitosis to spindle poles, spindle fibers, or condensed chromosomes.
###end p 27
###begin title 28
rTGFBI Protein Promotes Cell Adhesion and Microtubule Stabilization
###end title 28
###begin p 29
###xml 86 106 86 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35" ref-type="bibr">Palazzo et&#160;al., 2004</xref>
###xml 304 324 304 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35" ref-type="bibr">Palazzo et&#160;al., 2004</xref>
###xml 400 479 400 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib5 bib33 bib22 bib36" ref-type="bibr">Billings et&#160;al., 2002; Nam et&#160;al., 2003; Jeong and Kim, 2004; Park et&#160;al., 2004</xref>
###xml 592 600 592 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Figure&#160;4</xref>
###xml 759 769 759 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figures S5</xref>
Integrin-mediated adhesion of cells to fibronectin induces microtubule stabilization (Palazzo et al., 2004), suggesting that ECM and paclitaxel might have additive effects on microtubules. The stabilizing effect of fibronectin requires integrin-mediated focal adhesion kinase (FAK) activation and Rho A (Palazzo et al., 2004). TGFBI is known to mediate adhesion also in an integrin-dependent manner (Billings et al., 2002; Nam et al., 2003; Jeong and Kim, 2004; Park et al., 2004). This suggested a model where TGFBI could modulate paclitaxel sensitivity via microtubule stabilizing effects (Figure 4A). rTGFBI promoted adhesion of SKOV-3 cells, and this effect was partially antagonized by pretreating cells with a blocking antibody to alphaVbeta3 integrin (Figures S5A and S5B) (p < 0.001, two-sided t test).
###end p 29
###begin p 30
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Figure&#160;4</xref>
###xml 137 181 137 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12 bib35" ref-type="bibr">Gundersen et&#160;al., 1984; Palazzo et&#160;al., 2004</xref>
###xml 274 282 274 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Figure&#160;4</xref>
###xml 418 426 418 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Figure&#160;4</xref>
###xml 659 667 659 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Figure&#160;4</xref>
###xml 958 966 958 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Figure&#160;4</xref>
###xml 1280 1289 1280 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S5</xref>
###xml 1469 1478 1469 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S5</xref>
Figure 4B shows that cells plated on rTGFBI showed a significant increase in Glu-tubulin formation indicating microtubule stabilization (Gundersen et al., 1984; Palazzo et al., 2004). In addition, adhesion of cells to rTGFBI, or fibronectin, induced phosphorylation of FAK (Figure 4C). Attachment to fibronectin, but not to the integrin-independent adhesion peptide polylysine (PL), also showed Glu-tubulin formation (Figure 4D). To test whether FAK was required for microtubule stabilization by rTGFBI, we knocked down FAK in SKOV-3 cells using siRNAs, and these cells showed a significant decrease in microtubule stabilization following adhesion to rTGFBI (Figure 4E) (p < 0.001, two-sided t test). To test whether Rho A was also required for rTGFBI microtubule stabilization, Rho A was specifically inactivated using the cell permeable inhibitor C3 toxin. This resulted in a significant decrease in microtubule stabilization following adhesion to rTGFBI (Figure 4F) (p < 0.001, two-sided t test). These data confirmed that rTGFBI induced microtubule stabilization and that this required intact FAK and Rho A signaling. Extension of these experiments to nonmalignant cells using NIH 3T3 fibroblasts also showed that rTGFBI induced Glu-tubulin formation and FAK phosphorylation (Figure S5C). In addition, inactivation of Rho in NIH 3T3 cells using a dominant-negative Rho A expression construct significantly reduced the rTGFBI-mediated stabilization of microtubules (Figure S5D).
###end p 30
###begin title 31
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
rTGFBI Protein Sensitizes TGFBI-KD Cells to Paclitaxel in an Integrin-Dependent Manner
###end title 31
###begin p 32
###xml 241 249 241 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figure&#160;5</xref>
###xml 272 277 272 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 480 489 480 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figures 5</xref>
###xml 603 612 603 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figures 5</xref>
###xml 625 634 625 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S5</xref>
###xml 829 838 829 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 1009 1017 1009 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figure&#160;5</xref>
###xml 1151 1159 1151 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figure&#160;5</xref>
###xml 1453 1462 1453 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S1</xref>
###xml 1466 1475 1466 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figures 5</xref>
To test whether extracellular TGFBI was able to sensitize cells to the effect of paclitaxel, SKOV3-A and SKOV3-K cells were plated on rTGFBI-coated wells. This significantly increased paclitaxel-induced apoptosis (p < 0.001, two-way ANOVA) (Figure 5A). Importantly, KD of TGFBI significantly reduced the slope of the dose response curve for paclitaxel-induced Glu-tubulin formation (KD cells slope 1.3, 95% C. I. 0.6-2.1 versus SKOV-3 control cells slope 2.8, 95% C. I. 2.2-3.4) (Figures 5B and 5C). Plating KD cells on rTGFBI restored the slope of Glu-tubulin formation (slope 2.4, 95% C. I. 1.6-3.1) (Figures 5B and 5C and Figure S5E). SKOV-3TR cells plated on rTGFBI and treated with paclitaxel showed only a modest increase in apoptosis (data not shown), which we attributed to lower intracellular paclitaxel concentrations (Figure S2A). Increasing the level of intracellular paclitaxel by inhibiting paclitaxel efflux using verapamil significantly increased the sensitizing effect of rTGFBI in SKOV-3TR (Figure 5D). Verapamil also increased formation of stable microtubules in SKOV-3TR cells plated on rTGFBI following treatment with paclitaxel (Figure 5B). Control SKOV-3 cells plated on rTGFBI without paclitaxel treatment did not show increased caspase 3/7 activity (data not shown). We then tested whether rTGFBI was able to sensitize other paclitaxel-resistant ovarian cancer cells that had not been selected in vitro for resistance (see also Figure S1B). Figures 5E and 5F show that rTGFBI significantly increased paclitaxel-induced caspase activation in A2780 and PE0188 cells (p < 0.001, two-way ANOVA).
###end p 32
###begin p 33
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 165 173 165 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figure&#160;5</xref>
###xml 179 188 179 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S5</xref>
###xml 550 558 550 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figure&#160;5</xref>
###xml 564 573 564 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S5</xref>
###xml 878 886 878 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figure&#160;5</xref>
###xml 892 901 892 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S5</xref>
###xml 1008 1016 1008 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figure&#160;5</xref>
###xml 1022 1031 1022 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S5</xref>
Incubation of TGFBI-KD cells in serum-free media conditioned with rTGFBI also resulted in a significant reversal of paclitaxel resistance (p < 0.001 one-way ANOVA) (Figure 5G and Figure S5F). To test whether this sensitization was integrin dependent, we pretreated SKOV3-K cells with anti-alphaVbeta3 blocking antibody before exposure to rTGFBI-conditioned media. This pretreatment significantly reduced paclitaxel-induced apoptosis (p < 0.001, one-way ANOVA), confirming that rTGFBI binding to alphaVbeta3 was required for paclitaxel sensitization (Figure 5G and Figure S5F). To examine whether microtubule stabilization was required for rTGFBI-mediated paclitaxel sensitization, we blocked Rho and FAK pathways downstream of rTGFBI-integrin binding. Pretreatment with C3 toxin of SKOV3-KD cells for 4 hr before paclitaxel treatment decreased the sensitizing effect of rTGFBI (Figure 5G and Figure S5F). Similarly, transient knockdown of FAK using a single siRNA blocked the sensitizing effect of rTGFBI in Figure 5G and Figure S5F.
###end p 33
###begin p 34
###xml 142 180 142 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib23 bib47" ref-type="bibr">Judson et&#160;al., 1999; Sood et&#160;al., 2004</xref>
###xml 251 271 251 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35" ref-type="bibr">Palazzo et&#160;al., 2004</xref>
###xml 436 441 436 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 625 645 625 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib49" ref-type="bibr">Swanton et&#160;al., 2007</xref>
###xml 754 763 754 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S1</xref>
###xml 888 897 888 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S5</xref>
###xml 1009 1018 1009 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S5</xref>
FAK induces proliferation and survival in cancer cells, and therefore, downregulation of FAK was expected to sensitize cells to chemotherapy (Judson et al., 1999; Sood et al., 2004). However, FAK is required for ECM-induced microtubule stabilization (Palazzo et al., 2004), and our data suggested that loss of FAK might also induce paclitaxel resistance. We have recently shown using a RNAi screen for all kinases (in which, therefore, TGFBI was not included) that loss of FAK (PTK2) and its family member PTK2B induced paclitaxel resistance in A549 non-small-cell lung carcinoma and HCT116 colon cancer cells, respectively (Swanton et al., 2007). Transient knockdown of FAK in SKOV-3 and breast cancer MDA-MB-231 cells (defined as paclitaxel sensitive, Figure S1B) using independent siRNAs also induced significant resistance to paclitaxel-mediated apoptosis (p < 0.001, two-way ANOVA) (Figure S5G and data not shown). In addition, inhibition of Rho A resulted in resistance to paclitaxel induced apoptosis (Figure S5H). These results show that perturbing components of pathways involved in microtubule stability is sufficient to induce paclitaxel resistance.
###end p 34
###begin title 35
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
TGFBI Is Tightly Coexpressed with Fibronectin
###end title 35
###begin p 36
###xml 360 377 360 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Supplemental Data</xref>
###xml 382 391 382 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S6</xref>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
In parallel with the in vitro work, we carried out a prospective randomized clinical trial (CTCR-OV01) specifically designed to examine the molecular response to carboplatin and paclitaxel monotherapy in patients with advanced ovarian cancer. Tumor samples were collected prior to the start of neoadjuvant therapy and at subsequent interval debulking surgery (Supplemental Data and Figure S6A).
###end p 36
###begin p 37
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 232 237 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 436 441 436 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 513 521 513 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Table S2</xref>
###xml 567 570 567 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FN1</italic>
###xml 619 625 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL5A1</italic>
###xml 682 687 682 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THBS2</italic>
###xml 722 727 722 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THBS1</italic>
###xml 744 749 744 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THBS2</italic>
###xml 839 855 839 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib27" ref-type="bibr">Lih et&#160;al., 2006</xref>
###xml 993 998 993 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 1062 1070 1062 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Figure&#160;6</xref>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
As TGFBI is an integral component of the ECM, we investigated whether TGFBI expression correlated with the expression of other ECM transcripts that signal via integrins. We performed a correlation analysis between the expression of TGFBI and all other informative genes on the array (n = 3426), across all samples derived from patients treated with paclitaxel (n = 20), and ranked the genes according to their level of correlation with TGFBI. Strikingly, 18 out of the 20 top ranked genes were ECM-related genes (Table S2). Notably, these genes included fibronectin (FN1) (r = 0.89, Pearson correlation), collagen 5A1 (COL5A1) (r = 0.83, Pearson correlation), and thrombospondin-2 (THBS2) (r = 0.88, Pearson correlation). THBS1 is a homolog of THBS2 and was recently found to induce paclitaxel sensitivity through extracellular signaling (Lih et al., 2006). There was a significantly positive correlation between the probability of a gene being ECM-related and its degree of coexpression with TGFBI (r = 0.89, Pearson correlation; p < 0.001, linear regression) (Figure 6A).
###end p 37
###begin p 38
###xml 129 171 129 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib48 bib32" ref-type="bibr">Spentzos et&#160;al., 2005; Naderi et&#160;al., 2007</xref>
###xml 190 195 190 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 252 260 252 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Figure&#160;6</xref>
###xml 393 398 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THBS2</italic>
###xml 400 405 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THBS1</italic>
To confirm this finding in external data sets, we analyzed published expression microarray data from ovarian and breast cancers (Spentzos et al., 2005; Naderi et al., 2007). Coregulation of TGFBI with ECM genes was reproduced with striking similarity (Figure 6B and data not shown). Importantly, the top ranked coexpressed genes in these independent sets consistently included fibronectin and THBS2. THBS1 was also highly ranked in the Spentzos ovarian cancer data set (data not shown).
###end p 38
###begin title 39
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
TGFBI Is Underexpressed in Paclitaxel-Resistant Primary Ovarian Carcinoma Tissues
###end title 39
###begin p 40
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 518 523 518 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 623 631 623 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Figure&#160;6</xref>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 201 209 <span type="species:ncbi:9606">Patients</span>
###xml 435 443 <span type="species:ncbi:9606">Patients</span>
To determine whether TGFBI expression was associated with clinical paclitaxel resistance, we analyzed microarray expression data from twenty patients randomized to paclitaxel monotherapy in CTCR-OV01. Patients who showed paclitaxel resistance, as indicated by CA125 monitoring, had a significantly lower expression of TGFBI (p = 0.046, Wilcoxon test; 3.9% false discovery rate). RNA from 16/20 samples was available for real-time PCR. Patients who showed no paclitaxel response had a significantly lower expression of TGFBI (p = 0.0087, n = 16, Wilcoxon test) in their pretreatment samples compared to those who responded (Figure 6C).
###end p 40
###begin title 41
Centrosome Amplification Is Present in Paclitaxel-Resistant Ovarian Cancer Samples
###end title 41
###begin p 42
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 537 545 536 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Figure&#160;6</xref>
###xml 551 559 550 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Movie S1</xref>
###xml 908 916 907 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Figure&#160;6</xref>
###xml 707 715 <span type="species:ncbi:9606">patients</span>
###xml 850 858 <span type="species:ncbi:9606">patients</span>
As loss of TGFBI resulted in spindle deformities and centrosome amplification, we examined whether centrosome amplification correlated with paclitaxel resistance in clinical samples. To accurately count centrosomes in samples from the clinical study, we used three-dimensional reconstructions of confocal images from 20 mum tissue sections. Adequate amounts of tumor tissue were available in 10 pretreatment samples. Reconstructed images were scored by rotating the image to count the number of centrosomes associated with each nucleus (Figure 6D and Movie S1). Using this method, a total number of 2376 nuclei were examined in 10 cancer samples, and counting was performed blind to the clinical outcome of patients. We found a significantly higher (p = 0.019, Wilcoxon test) proportion of cells with centrosome amplification in paclitaxel-resistant patients (7.6%) compared to paclitaxel responders (3.9%) (Figure 6E).
###end p 42
###begin title 43
Paclitaxel-Induced Cell Death in Ovarian Cancer Samples Colocalizes with Areas of High TGFBI Protein Expression
###end title 43
###begin p 44
###xml 300 319 300 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib42" ref-type="bibr">Seiler et&#160;al., 2004</xref>
###xml 388 396 388 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Figure&#160;6</xref>
###xml 402 412 402 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figures S6</xref>
###xml 547 555 547 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Figure&#160;6</xref>
###xml 561 570 561 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S6</xref>
###xml 881 890 881 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S6</xref>
We next examined ovarian cancer samples taken after paclitaxel treatment from the CTCR-OV01 study using immunohistochemistry for TGFBI. Sections of ovarian cancer tissue revealed morphological changes typical of paclitaxel-induced cytotoxicity, including cytoplasmic vacuolation and multinucleation (Seiler et al., 2004), and these changes were localized to areas of high TGFBI staining (Figure 6F and Figures S6B and S6C). TGFBI labeling was absent in the ECM around neighboring cells lacking paclitaxel-induced changes and in areas of necrosis (Figure 6F and Figure S6D). Positive TGFBI staining was significantly associated with evidence of paclitaxel-induced cytotoxicity (n = 14, p = 0.0035, Chi square test with Monte-Carlo simulation). Importantly, focal TGFBI staining was present in pretreatment samples; however cytoplasmic vacuolation and multinucleation were not seen (Figure S6E).
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 244 266 244 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12" ref-type="bibr">Gundersen et&#160;al., 1984</xref>
###xml 433 441 433 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig7" ref-type="fig">Figure&#160;7</xref>
###xml 588 650 588 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib11 bib4 bib15" ref-type="bibr">Gon&#231;alves et&#160;al., 2001; Barlow et&#160;al., 2002; Hari et&#160;al., 2006</xref>
###xml 781 786 781 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 1022 1067 1022 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib11 bib29" ref-type="bibr">Gon&#231;alves et&#160;al., 2001; Martello et&#160;al., 2003</xref>
###xml 1161 1181 1158 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib46" ref-type="bibr">Skonier et&#160;al., 1992</xref>
###xml 1288 1310 1282 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib13" ref-type="bibr">Gundersen et&#160;al., 1994</xref>
###xml 1605 1651 1599 1645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35 bib3" ref-type="bibr">Palazzo et&#160;al., 2004; Baldassarre et&#160;al., 2005</xref>
Our results suggest that the ECM protein TGFBI modulates paclitaxel response via regulation of microtubule stability. Acetylated and detyrosinated microtubules define a stable subpopulation of microtubule polymers that resist depolymerization (Gundersen et al., 1984). This population is less dynamic compared to unstable microtubules and, therefore, less likely to contribute to the proportion of depolymerized tubulin in the cell (Figure 7). As paclitaxel primarily targets polymerized microtubules, an increase in the proportion of unstable microtubules induces paclitaxel resistance (Goncalves et al., 2001; Barlow et al., 2002; Hari et al., 2006). We show that extracellular TGFBI stabilized microtubules and increased sensitivity to paclitaxel. Conversely, selective loss of TGFBI by KD resulted in mitotic spindle abnormalities and paclitaxel resistance. These findings mimic previous results from cell lines with intracellular alterations of tubulin that also caused paclitaxel resistance and mitotic instability (Goncalves et al., 2001; Martello et al., 2003). TGFBI was originally identified as induced by TGFbeta stimulation in adenocarcinoma cells (Skonier et al., 1992), and our results may explain how TGFbeta induces microtubule stabilization in serum-starved fibroblasts (Gundersen et al., 1994). Recombinant TGFBI induced microtubule stabilization that was dependent on integrin-mediated FAK and Rho signaling. The exact mechanisms of microtubule stabilization downstream of FAK and Rho remain unknown but may include mDIA1 or inactivation of the microtubule associated protein stathmin (Palazzo et al., 2004; Baldassarre et al., 2005).
###end p 46
###begin p 47
###xml 299 341 296 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib43 bib17" ref-type="bibr">Sethi et&#160;al., 1999; Hodkinson et&#160;al., 2006</xref>
###xml 483 499 480 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib27" ref-type="bibr">Lih et&#160;al., 2006</xref>
###xml 521 526 518 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
The relationship between ECM proteins and drug resistance is likely to be complex. Previous studies have shown that ECM proteins induced resistance to DNA-damaging drugs such as cisplatin and etoposide, and decreased apoptosis was associated with beta1-integrin-mediated activation of PI3K and AKT (Sethi et al., 1999; Hodkinson et al., 2006). In contrast, the ECM protein THBS1 sensitizes pancreatic cancer cells specifically to taxane-induced apoptosis in a CD47-dependent manner (Lih et al., 2006). Here, we show that TGFBI is tightly coexpressed with THBS1 in ovarian and breast cancers. It is possible that the two proteins may cooperate to induce taxane sensitization through activating CD47-driven pathways (THBS1) and integrin-mediated microtubule stabilization (TGFBI). The finding that the protein expression of TGFBI in tissue samples treated with paclitaxel monotherapy, specifically colocalized with areas of taxane-induced cytotoxicity suggests that TGFBI, and possibly other ECM proteins, modulate taxane effects in vivo. Our data extend previous reports and suggests that the specific molecular targets of individual drugs are likely to determine whether the effect of the ECM is agonistic or antagonistic with chemotherapy.
###end p 47
###begin p 48
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 305 341 305 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib44 bib56" ref-type="bibr">Shao et&#160;al., 2006; Zhao et&#160;al., 2006</xref>
###xml 622 660 622 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib23 bib47" ref-type="bibr">Judson et&#160;al., 1999; Sood et&#160;al., 2004</xref>
###xml 758 777 758 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr">Hecker et&#160;al., 2002</xref>
###xml 825 843 825 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib45" ref-type="bibr">Sheta et&#160;al., 2000</xref>
###xml 946 966 946 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib9" ref-type="bibr">Duxbury et&#160;al., 2004</xref>
###xml 1136 1156 1136 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35" ref-type="bibr">Palazzo et&#160;al., 2004</xref>
###xml 1331 1350 1331 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib14" ref-type="bibr">Halder et&#160;al., 2005</xref>
###xml 1505 1525 1505 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib49" ref-type="bibr">Swanton et&#160;al., 2007</xref>
###xml 1598 1615 1598 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib47" ref-type="bibr">Sood et&#160;al., 2004</xref>
###xml 1568 1576 <span type="species:ncbi:9606">patients</span>
###xml 1659 1667 <span type="species:ncbi:9606">patients</span>
Importantly the findings reported here have potentially significant clinical implications. First, TGFBI protein expression is lost in a third of primary ovarian cancers (A.A.A., A.E.K.I., and J.D.B., unpublished data) and TGFBI has previously been shown to be methylated and downregulated in lung cancer (Shao et al., 2006; Zhao et al., 2006). Future studies should correlate the expression of TGFBI with taxane response to test the value of TGFBI as a predictive biomarker. Second, in ovarian cancer, FAK is overexpressed, plays a role in regulating invasion and metastasis, and is associated with poor clinical outcome (Judson et al., 1999; Sood et al., 2004). FAK also regulates tumor growth either directly, through activation of ERK-dependent pathways (Hecker et al., 2002), or indirectly through inducing angiogenesis (Sheta et al., 2000). Downregulation of FAK using siRNAs results in inhibited growth and metastasis of pancreatic cancer (Duxbury et al., 2004) and could, therefore, be attractive therapeutically. However, previous studies have demonstrated that FAK is required for adhesion-dependent microtubule stabilization (Palazzo et al., 2004). In the current study, loss of FAK or Rho A blocked microtubule stabilization and paclitaxel sensitization by rTGFBI. Importantly, and in contrast to previous publications (Halder et al., 2005), our results show that loss of FAK results in increased resistance to taxanes, and this was confirmed using independent siRNAs and experimental studies (Swanton et al., 2007). As FAK is low or absent in one-third of patients with ovarian cancer (Sood et al., 2004), it could be used as a marker to identify patients who may not benefit from paclitaxel treatment. Furthermore, although downregulation of FAK may also induce growth inhibition, our data argue against combining FAK inhibitors with paclitaxel treatment.
###end p 48
###begin p 49
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 423 479 423 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21" ref-type="bibr">International Collaborative Ovarian Neoplasm Group, 2002</xref>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
We describe here a mechanism of specific paclitaxel sensitization via induction of microtubule stabilization by the ECM protein TGFBI. Furthermore, we show that expression of TGFBI in ovarian and breast tumors is tightly coregulated with other ECM proteins that either induce microtubule stabilization or paclitaxel sensitization. The effectiveness of taxanes in improving survival in ovarian cancer remains controversial (International Collaborative Ovarian Neoplasm Group, 2002), and TGFBI could be used as a biomarker for selecting patients for taxane therapy. In addition, as TGFBI is an ECM protein, activating peptides or antibodies that mimic its action may be a strategy for modulation of response to taxane chemotherapy.
###end p 49
###begin title 50
Experimental Procedures
###end title 50
###begin title 51
Cambridge Translational Cancer Research Ovary 01 Study
###end title 51
###begin p 52
###xml 43 79 43 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
The details of this study are described in Supplemental Experimental Procedures. The study was approved by the Cambridge Local Research Ethics Committee (LREC). All patients gave written informed consent prior to participation.
###end p 52
###begin title 53
Cell Culture
###end title 53
###begin p 54
###xml 158 164 <span type="species:ncbi:9913">bovine</span>
Cell lines were obtained from Cell Services (Cancer Research UK London Research Institute) and were maintained in RPMI 140 medium supplemented with 10% fetal bovine serum, penicillin, and streptomycin and incubated at 37degreesC and 5% CO2. SKOV-3TR cells were maintained in 0.3 muM paclitaxel.
###end p 54
###begin title 55
Apoptosis Assays, Annexin V Binding, and Flow Cytometric Analyses
###end title 55
###begin p 56
###xml 992 1009 990 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib53" ref-type="bibr">Wang et&#160;al., 1998</xref>
###xml 517 522 <span type="species:ncbi:10090">mouse</span>
Cells were grown in 6-well plates to 80% confluence before paclitaxel, nocodazole, cisplatin, or verapamil treatment (Sigma). For rTGFBI pretreatment experiments, adherent cells in 24-well tissue culture plates were incubated with rTGFBI at 50 mug/ml in serum-free media (SFM) for 2 hr followed by paclitaxel treatment for 1 hr to make up the required concentrations. Cells were then washed with PBS and incubated with normal media for 48 hr. For integrin-blocking experiments, attached cells were incubated with the mouse monoclonal antibody anti-alphaVbeta3 (Chemicon) for 1 hr (1 in 100 dilution) in SFM. Rho A inhibition in SKOV-3 cells was achieved by treating attached cells with 2 mug/ml cell permeable C3 transferase recombinant protein (Cytoskeleton) in SFM for 4 hr prior to paclitaxel treatment for 1 hr. Early apoptosis was estimated using apoptosis detection kit (R & D systems) and 7-AAD (Molecular Probes) following the manufacturers' instructions and as previously described (Wang et al., 1998). Flow cytometric analysis was performed with a LSR II flow cytometer (BD bioscience) and analyzed with the FACSDiva software (BD bioscience).
###end p 56
###begin title 57
Caspase 3 and 7 Assays
###end title 57
###begin p 58
###xml 135 136 135 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
We first confirmed the optimum number of cells and linear range for paclitaxel dose response for the assay. Cells were plated at 1 x 104 cells per well in a 384-well plate in 20 mul volume overnight before paclitaxel was added in 10 mul volume to reach the final indicated concentrations. Caspase 3/7 activity was estimated 48 hr following treatment by adding 30 mul of the Caspase-Glo 3/7 Assay reagent (Promega). Luminescence was read following at least 1 hr of incubation on a luminescence plate reader (Infinite M200, Tecan) using the i-control software (Tecan).
###end p 58
###begin title 59
Supplemental Data
###end title 59
###begin p 60
The Supplemental Data include Supplemental Experimental Procedures, five supplemental figures, two supplemental tables, and one supplemental movie and can be found with this article online at .
###end p 60
###begin title 61
Supplemental Data
###end title 61
###begin p 62
###xml 0 105 0 105 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="63">Document S1. Supplemental Experimental Procedures, Five Supplemental Figures, and Two Supplemental Tables</title>
###xml 0 105 0 105 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="63">Document S1. Supplemental Experimental Procedures, Five Supplemental Figures, and Two Supplemental Tables</title></caption>
###xml 105 105 105 105 <media xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/>
###xml 0 105 0 105 <supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="mmc1"><caption><title textid="63">Document S1. Supplemental Experimental Procedures, Five Supplemental Figures, and Two Supplemental Tables</title></caption><media xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material>
###xml 105 209 105 209 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="64">Movie S1. Three-Dimensional Reconstruction and Rotation Is Required for Accurate Counting of Centrosomes</title>
###xml 105 209 105 209 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="64">Movie S1. Three-Dimensional Reconstruction and Rotation Is Required for Accurate Counting of Centrosomes</title></caption>
###xml 209 567 209 563 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="65">Three-dimensional (3D) reconstruction and rotation of Z stack images obtained following double immunofluorescent staining of a representative ovarian carcinoma tissue section. Reconstructed images were scored by rotating the image to count the number of centrosomes associated with each nucleus. Anti-&#947; tubulin, green; chromosomal DNA, Hoechst 33258 red.</p>
###xml 567 567 563 563 <media xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="mmc2.mov" mimetype="video" mime-subtype="quicktime"/>
###xml 105 567 105 563 <supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="mmc2"><caption><title textid="64">Movie S1. Three-Dimensional Reconstruction and Rotation Is Required for Accurate Counting of Centrosomes</title></caption><p textid="65">Three-dimensional (3D) reconstruction and rotation of Z stack images obtained following double immunofluorescent staining of a representative ovarian carcinoma tissue section. Reconstructed images were scored by rotating the image to count the number of centrosomes associated with each nucleus. Anti-&#947; tubulin, green; chromosomal DNA, Hoechst 33258 red.</p><media xlink:href="mmc2.mov" mimetype="video" mime-subtype="quicktime"/></supplementary-material>
Document S1. Supplemental Experimental Procedures, Five Supplemental Figures, and Two Supplemental TablesMovie S1. Three-Dimensional Reconstruction and Rotation Is Required for Accurate Counting of CentrosomesThree-dimensional (3D) reconstruction and rotation of Z stack images obtained following double immunofluorescent staining of a representative ovarian carcinoma tissue section. Reconstructed images were scored by rotating the image to count the number of centrosomes associated with each nucleus. Anti-gamma tubulin, green; chromosomal DNA, Hoechst 33258 red.
###end p 62
###begin title 63
Document S1. Supplemental Experimental Procedures, Five Supplemental Figures, and Two Supplemental Tables
###end title 63
###begin title 64
Movie S1. Three-Dimensional Reconstruction and Rotation Is Required for Accurate Counting of Centrosomes
###end title 64
###begin p 65
Three-dimensional (3D) reconstruction and rotation of Z stack images obtained following double immunofluorescent staining of a representative ovarian carcinoma tissue section. Reconstructed images were scored by rotating the image to count the number of centrosomes associated with each nucleus. Anti-gamma tubulin, green; chromosomal DNA, Hoechst 33258 red.
###end p 65
###begin title 66
Accession Numbers
###end title 66
###begin p 67
The microarray data tables are available from the Gene Expression Omnibus (GEO) at . Series numbers, GSE2627 and GSE9455 for cell lines and CTCR-OV01 study, respectively.
###end p 67
###begin title 68
Acknowledgments
###end title 68
###begin p 69
###xml 349 357 <span type="species:ncbi:9606">patients</span>
This work was supported by Cancer Research UK (CR-UK) and the Medical Research Council (MRC). A.A.A. and C.S. hold CR-UK Clinician Scientist Fellowships. C.B. was funded by the National Translational Cancer Research Network (NTRAC). N.G.I. was a recipient of a National Medical Research Council (Singapore) Medical Research Fellowship. We thank our patients and members of the Gynaecological Oncology Multidisciplinary Team at Cambridge University Hospitals NHS Foundation Trust for their participation in the CTCR-OV01 clinical study. We thank Drs. Shin-Ichi Ohnuma, Daniel F. Schorderet, and Ching Yuan for gifts of reagents; Dr. Andrew E. Teschendorff for sharing unpublished data; and Lysa Baginsky and John Brown for expert technical assistance. We are also grateful to Drs. Fanni Gergely, Masashi Narita, and Natalie Thorne for helpful discussions.
###end p 69
###begin title 70
References
###end title 70
###begin article-title 71
###xml 66 71 <span type="species:ncbi:9606">human</span>
Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer
###end article-title 71
###begin article-title 72
AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol
###end article-title 72
###begin article-title 73
p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion
###end article-title 73
###begin article-title 74
Paclitaxel-dependent mutants have severely reduced microtubule assembly and reduced tubulin synthesis
###end article-title 74
###begin article-title 75
The transforming growth factor-beta-inducible matrix protein (beta)ig-h3 interacts with fibronectin
###end article-title 75
###begin article-title 76
Rho guanosine triphosphatase mediates the selective stabilization of microtubules induced by lysophosphatidic acid
###end article-title 76
###begin article-title 77
TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line
###end article-title 77
###begin article-title 78
Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines
###end article-title 78
###begin article-title 79
###xml 83 88 <span type="species:ncbi:9606">human</span>
Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells
###end article-title 79
###begin article-title 80
###xml 21 26 <span type="species:ncbi:9606">human</span>
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization
###end article-title 80
###begin article-title 81
Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics
###end article-title 81
###begin article-title 82
Distinct populations of microtubules: Tyrosinated and nontyrosinated alpha tubulin are distributed differently in vivo
###end article-title 82
###begin article-title 83
Induction of stable microtubules in 3T3 fibroblasts by TGF-beta and serum
###end article-title 83
###begin article-title 84
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells
###end article-title 84
###begin article-title 85
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules
###end article-title 85
###begin article-title 86
Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples
###end article-title 86
###begin article-title 87
ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase
###end article-title 87
###begin article-title 88
###xml 112 117 <span type="species:ncbi:9606">human</span>
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease
###end article-title 88
###begin article-title 89
###xml 99 104 <span type="species:ncbi:9606">human</span>
Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells
###end article-title 89
###begin article-title 90
###xml 159 164 <span type="species:ncbi:9606">human</span>
Temporal relationship of CDK1 activation and mitotic arrest to zytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells
###end article-title 90
###begin article-title 91
###xml 145 150 <span type="species:ncbi:9606">women</span>
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial
###end article-title 91
###begin article-title 92
TGF-beta1 enhances betaig-h3-mediated keratinocyte cell migration through the alpha3beta1 integrin and PI3K
###end article-title 92
###begin article-title 93
Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma
###end article-title 93
###begin article-title 94
Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein
###end article-title 94
###begin article-title 95
Mitotic spindle assembly and chromosome segregation: Refocusing on microtubule dynamics
###end article-title 95
###begin article-title 96
###xml 70 75 <span type="species:ncbi:9606">human</span>
Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line
###end article-title 96
###begin article-title 97
Txr1: A transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes
###end article-title 97
###begin article-title 98
###xml 100 110 <span type="species:ncbi:7227">Drosophila</span>
Different spindle checkpoint proteins monitor microtubule attachment and tension at kinetochores in Drosophila cells
###end article-title 98
###begin article-title 99
Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation
###end article-title 99
###begin article-title 100
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III/IV ovarian cancer)
###end article-title 100
###begin article-title 101
###xml 106 114 <span type="species:ncbi:9606">patients</span>
Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients
###end article-title 101
###begin article-title 102
A gene-expression signature to predict survival in breast cancer across independent data sets
###end article-title 102
###begin article-title 103
Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect
###end article-title 103
###begin article-title 104
How cells get the right chromosomes
###end article-title 104
###begin article-title 105
Localized stabilization of microtubules by integrin- and FAK-facilitated Rho signaling
###end article-title 105
###begin article-title 106
Beta ig-h3 promotes renal proximal tubular epithelial cell adhesion, migration and proliferation through the interaction with alpha3beta1 integrin
###end article-title 106
###begin article-title 107
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 132 137 <span type="species:ncbi:10090">mouse</span>
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models
###end article-title 107
###begin article-title 108
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
###end article-title 108
###begin article-title 109
Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest
###end article-title 109
###begin article-title 110
Promotion of microtubule assembly in vitro by taxol
###end article-title 110
###begin article-title 111
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
Taxol stabilizes microtubules in mouse fibroblast cells
###end article-title 111
###begin article-title 112
Polyploidisation of metastatic colon carcinoma cells by microtubule and tubulin interacting drugs: Effect on proteolytic activity and invasiveness
###end article-title 112
###begin article-title 113
Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo
###end article-title 113
###begin article-title 114
###xml 45 50 <span type="species:ncbi:9606">human</span>
Epigenetic inactivation of Betaig-h3 gene in human cancer cells
###end article-title 114
###begin article-title 115
Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor
###end article-title 115
###begin article-title 116
###xml 76 81 <span type="species:ncbi:9606">human</span>
cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta
###end article-title 116
###begin article-title 117
Biological significance of focal adhesion kinase in ovarian cancer: Role in migration and invasion
###end article-title 117
###begin article-title 118
Unique gene expression profile based on pathologic response in epithelial ovarian cancer
###end article-title 118
###begin article-title 119
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs
###end article-title 119
###begin article-title 120
Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis
###end article-title 120
###begin article-title 121
Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor
###end article-title 121
###begin article-title 122
Mn-SOD antisense upregulates in vivo apoptosis of squamous cell carcinoma cells by anticancer drugs and gamma-rays regulating expression of the BCL-2 family proteins, COX-2 and p21
###end article-title 122
###begin article-title 123
Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways
###end article-title 123
###begin article-title 124
Intra-allelic suppression of a mutation that stabilizes microtubules and confers resistance to colcemid
###end article-title 124
###begin article-title 125
The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells
###end article-title 125
###begin article-title 126
Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells
###end article-title 126
###begin p 127
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
Loss of TGFBI Is Sufficient to Induce Paclitaxel Resistance
###end p 127
###begin p 128
(A) Volcano plot shows log fold change in gene expression in the paclitaxel-resistant cell line SKOV-3TR compared to the sensitive parental line SKOV-3 and plotted against the likelihood of differential expression. Note that negative log2 expression ratios indicate underexpression in SKOV-3TR. Data points represent the probability value for differential gene expression and data shown is from four replicate experiments.
###end p 128
###begin p 129
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
(B) Relative expression levels of TGFBI in different cell lines using real time PCR.
###end p 129
###begin p 130
(C) Immunocytochemistry of stained sections from embedded cell pellets using anti-TGFBI antibody. Scale bars, 10 mum.
###end p 130
###begin p 131
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
(D) Western blotting of culture medium from SKOV-3TR, mock-transfected SKOV-3, and TGFBI siRNA-transfected SKOV3-K cell lines probed with anti-TGFBI antibody.
###end p 131
###begin p 132
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
(E) Effect of stable KD of TGFBI (SKOV3-A, SKOV3-K, and SKOV3-AK) on paclitaxel-induced apoptosis measured by FITC-annexin V and 7-AAD staining at 48 hr following paclitaxel treatment (150, 300, 600, 1200, and 2000 nM) compared to SKOV-3, mock-transfected SKOV-3 (mtSKOV3), and SKOV-3TR cells. Filled triangle indicates increasing paclitaxel dose across each group of bars.
###end p 132
###begin p 133
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
(F) Effect of stable KD of TGFBI on caspase 3/7 activation 48 hr following paclitaxel treatment.
###end p 133
###begin p 134
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 194 199 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
(G and H) Transient TGFBI-KD in OVCAR3 and TR175 lines induces paclitaxel resistance. Caspase 3/7 activation was estimated 48 hr following transfection using either a pool of 4 siRNAs targeting TGFBI or nontargeting scrambled controls (sc). OVCAR3 cells (G) or TR175 cells (H) were treated with paclitaxel for 48 hr. Immunoblot confirming knockdown of TGFBI protein is shown in (G). Error bars show mean +/- SD.
###end p 134
###begin p 135
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
Loss of TGFBI Causes Defective Paclitaxel-Induced Microtubule Polymerization
###end p 135
###begin p 136
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
(A-F) Overexpression of TGFBI in SKOV-3TR by pCSMT-TGFBI sensitizes microtubules to the polymerizing effect of paclitaxel. Arrowheads indicate paclitaxel-induced bundles (PIBs). Green, tubulin; blue, Dapi-stained DNA. Scale bars, 10 mum.
###end p 136
###begin p 137
(G) Paclitaxel induces Glu-tubulin formation. Cells were serum starved for 24 hr then treated with paclitaxel in serum-free medium (SFM) at 0, 4, 16, 75, 300, and 1200 nM concentrations for 1 hr. Lysates were collected for fluorescence immuno-blotting with anti-Glu-tubulin and anti-alpha tubulin. Bars represent the fold increase in Glu-tubulin fluorescence intensity values normalized for alpha-tubulin intensity values. Filled triangle indicates increasing paclitaxel dose across each group of bars.
###end p 137
###begin p 138
(H) A fluorescence immunoblot of soluble (sol) and insoluble (insol) tubulin fractions.
###end p 138
###begin p 139
###xml 292 328 292 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>
(I) SKOV-3TR and SKOV3-K cells have increased soluble tubulin. Graph shows the percentages of soluble tubulin in relation to total tubulin in the different cell lines. Quantitative measurements were performed using fluorescence immunoblotting with anti-alpha tubulin antibody as described in Supplemental Experimental Procedures. Results shown are from two independent experiments. Horizontal bars indicate median values.
###end p 139
###begin p 140
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
Loss of TGFBI Induces Mitotic Abnormalities
###end p 140
###begin p 141
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
(A and B) Stable KD of TGFBI in SKOV-3 cells results in abnormal mitotic spindle formation and centrosome amplification. Magenta, tubulin; blue, Dapi-stained DNA; yellow, gamma tubulin.
###end p 141
###begin p 142
(C) Proportion of abnormal mitotic cells at 9-30 days in SKOV-3TR, stable knockdown, and mock transfected (mt) cell line pools.
###end p 142
###begin p 143
(D) Proportion of interphase cells showing centrosome amplification. Number of cells counted is shown above corresponding bars.
###end p 143
###begin p 144
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
(E) Proportion of abnormal mitotic cells after 48 hr following transient knockdown of TGFBI using a pool of four siRNAs. Error bars show mean +/- SD.
###end p 144
###begin p 145
TGFBI Induces Microtubule Stabilization
###end p 145
###begin p 146
(A) Model of TGFBI induction of microtubule stabilization.
###end p 146
###begin p 147
(B) Microtubule stabilization demonstrated with anti-Glu tubulin antibody. SKOV-3 cells were plated for 90 min on rTGFBI or polylysine-coated glass slides (20 mug/ml) before immunofluorescence. Scale bars, 10 mum.
###end p 147
###begin p 148
(C) Cells were adhered to polylysine, fibronectin, or rTGFBI-coated wells (20 mug/ml) for 90 min before lysates were collected for immunoblotting using anti-phosphorylated FAK (P397). Also shown are immunoblots for lysates of cells treated in suspension with or without paclitaxel at 3 muM.
###end p 148
###begin p 149
(D) Percentages of SKOV-3 cells showing Glu-tubulin following adhesion to rTGFBI, fibronectin, or polylysine.
###end p 149
###begin p 150
(E) 48 hr following transfection using either FAK siRNA or nontargeting siRNAs, SKOV-3 cells were plated on rTGFBI coated glass slides for 90 min and the percentage of cells showing Glu-tubulin formation was estimated by immunofluorescence.
###end p 150
###begin p 151
(F) SKOV-3 cells were either treated with the Rho A inhibitor C3 toxin in SFM or with SFM alone for 4 hr before plating on rTGFBI-coated glass slides and estimation of Glu-tubulin formation. Error bars show mean +/- SD.
###end p 151
###begin p 152
rTGFBI Sensitizes Resistant Cells to the Effect of Paclitaxel
###end p 152
###begin p 153
(A) Cells were adhered to rTGFBI-coated wells (20 mug/ml) or noncoated wells for 24 hr prior to paclitaxel treatment for 48 hr. Shown is the percentage of apoptotic cells as measured using FITC-annexin V and 7-AAD staining.
###end p 153
###begin p 154
(B) Cells were serum starved for 24 hr then treated with paclitaxel in serum-free medium (SFM) at 0, 4, 16, 75, 300, and 1200 nM concentrations for 1 hour before lysates were collected for fluorescence immunoblotting using anti-Glu-tubulin and anti-alpha tubulin. Bars represent the fold increase in glu-tubulin fluorescence intensity values normalized for alpha tubulin intensity values. Filled triangle indicates increasing paclitaxel dose across each group of bars.
###end p 154
###begin p 155
(C) The slope and 95% confidence intervals for the linear regression of Glu-tubulin formation following paclitaxel treatment in SKOV-3 and mtSKOV3 (SKOV3-WT), SKOV3-A and SKOV3-K (SKOV3-KD), and SKOV3-KD following plating on rTGFBI.
###end p 155
###begin p 156
(D) SKOV-3TR cells were either plated on plastic or rTGFBI as in (A) and either treated with paclitaxel alone (SKOV3-TR) or with paclitaxel and verapamil 3.3 muM (TR + V and TR + V + rTGFBI) for 48 hr before caspase 3/7 activity was estimated. Also shown is the data for the parental sensitive line (SKOV-3) plated on plastic.
###end p 156
###begin p 157
(E and F) A2780 Cells (E) or PE0188 cells (F) were either plated on plastic or on rTGFBI (20 mug/ml) before paclitaxel treatment for 48 hr. Shown is the fold increase in caspase 3/7 activity.
###end p 157
###begin p 158
(G) Cells were either pretreated with 50 mug/ml of rTGFBI in SFM or SFM alone for 2 hr followed by paclitaxel treatment for 1 hr, washing, and incubation in full media for 48 hr. Shown is the percentage of apoptotic cells measured by FITC-annexin V and 7-AAD staining. A+rTGFBI+anti-alphaVbeta3; SKOV3-A cells pretreated with anti-alphaVbeta3 in SFM before treatment with rTGFBI and paclitaxel, A+rTGFBI+FAK-KD; SKOV3-A cells were transfected with siRNA targeting FAK 48 hr prior to rTGFBI and paclitaxel treatment, A+rTGFBI+C3-toxin; SKOV3-A cells were pretreated with the Rho A inhibitor, C3 toxin, in SFM for 4 hr before the application of rTGFBI and paclitaxel. Error bars show mean +/- SD.
###end p 158
###begin p 159
The ECM Protein TGFBI Sensitizes Ovarian Carcinoma Cells In Vivo to the Effect of Paclitaxel
###end p 159
###begin p 160
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 126 148 126 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib48" ref-type="bibr">Spentzos et&#160;al. (2005)</xref>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 251 256 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
Correlation between expression of TGFBI and ECM genes in (A) CTCR-OV01 study and (B) independent ovarian cancer data set from Spentzos et al. (2005). Graphs show proportion of ECM-related genes increasing as a function of coexpression with TGFBI. (C) TGFBI expression in pretreatment biopsies of advanced ovarian carcinoma using real-time PCR. Resistant cases (n = 5; magenta) are compared to sensitive cases (n = 11; green). (D) Three-dimensional reconstruction of Z stack images obtained following double immunofluorescent staining of a representative ovarian carcinoma tissue section. Arrowheads indicate amplified centrosomes in a single cell confirmed by examination in all three planes. Anti-gamma tubulin, green; chromosomal DNA, Hoechst 33258 red. Scale bar, 10 mum. (E) Centrosome amplification is associated with paclitaxel resistance. Centrosome counting was performed on samples from which adequate frozen tissue was available (n = 10; samples common between [C] and [E] are indicated by squares). In (C) and (E), horizontal bars indicate median values. (F) Immunohistochemistry for TGFBI of representative posttreatment ovarian cancer sample. Paclitaxel-induced morphological changes colocalize with focal TGFBI expression (brown staining, green box 1) but not in areas of low TGFBI expression (magenta box 2). Scale bars for main subfigure and boxes, 500 mum and 50 mum, respectively.
###end p 160
###begin p 161
Proposed Model of Modulation of Paclitaxel Resistance by TGFBI via Effects on Microtubule Stability
###end p 161

